# Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

> **NCT04981912** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Diego** · enrollment: 4 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** HDMP + rituximab as a means of debulking prior to initiating venetoclax.

## Key facts

- **NCT ID:** NCT04981912
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-02
- **Primary completion:** 2025-07-22
- **Final completion:** 2026-07-22
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981912, "Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04981912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*